Genprex, Inc. (GNPX) Research

Genprex, Inc. is a biotechnology firm specializing in gene therapy, with its primary focus on advancing treatments through clinical stages. Their mission revolves around developing innovative therapies for patients battling cancer and diabetes. Leading their product pipeline is REQORSA (GPX-001), a flagship gene therapy candidate specifically designed to target both non-small cell lung cancer and small cell lung cancer. In addition, Genprex is progressing GPX-002, another gene therapy at the preclinical stage, intended for the management of diabetes. The company was established in 2009 and operates from its corporate headquarters located in Austin, Texas.

Market snapshot

Symbol
GNPX
Price
$0.59
Day change
+22.47%
Market cap
$966.0K
P/E ratio
-0.25x
52-week range
0.423-55
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months

Peer companies

  • Biodexa Pharmaceuticals Plc (BDRX)
  • BioVie Inc. (BIVI)
  • CERo Therapeutics Holdings, Inc. (CERO)
  • Chemomab Therapeutics Ltd. (CMMB)
  • CNS Pharmaceuticals, Inc. (CNSP)
  • GRI Bio, Inc. (GRI)
  • InMed Pharmaceuticals Inc. (INM)
  • Jaguar Health, Inc. (JAGX)

Recent insider activity

  • LONGNECKER BRENT M — S-Sale (8 shares) on 2026-04-14
  • LONGNECKER BRENT M — S-Sale (10 shares) on 2026-04-14
  • Berger Mark Stanley — F-InKind (7168 shares) on 2026-02-27
  • Confer Ryan M. — F-InKind (9330 shares) on 2026-02-27
  • Moreno Toscano Jose Antonio — A-Award (9000 shares) on 2025-12-22

Open Genprex, Inc. (GNPX) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.